Ipsen SAPharma giant Ipsen will pay US$1bn to acquire French immuno-oncology firm ImCheck Therapeutics SAS. The deal includes US$350m upfront and up to US$650m in milestone payments. ImCheck focuses on butyrophilins, a new class of immune regulators, through its antibody programme ICT01, currently in Phase I trials.
Tag Archive for: antibody
Alchemab Therapeutics LtdBritish antibody specialist Alchemab Therapeutics Ltd has secured a US$32m Series A extension after it completing preclinical development of ATLX-1282 and starting a Phase I clinical trial.
Johnson & JohnsonThe case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game and has now full ownership while expanding the indications further.
robin_24, WikipediaLeyden Labs has raised $70 million in a funding round led by ClavystBio and Polaris Partners, boosting its efforts to develop intranasal antibody therapies targeting respiratory viruses, including influenza and coronaviruses.
Molcure IncGerman antibody specialist YUMAB GmbH has inked a collaboration agreement with Japanese MOLCURE Inc aimed at using the company’s zero-shot AI technology for antibody discovery.
EIBFab’entech, a French biopharma company, has secured a loan worth €20m from the European Investment Bank (EIB) under the HERA Invest programme, aimed at bolstering Europe’s preparedness against biological threats.
King's CollegeA new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept for MOv18 IgE.
Antibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.
London-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.
Belgian AgTech specialist Biotalys BV an Agricultural Technology (AgTech) company has initiated field trials for BioFun-6, the company’s second llama-antibody-mimicking biofungicide program.
Tag Archive for: antibody
The 16th World ADC London takes place on 23–26 February 2026, bringing together over 800 senior decision-makers from biopharma, KOL oncologists, service providers, investors, and regulators. As Europe’s largest forum dedicated to antibody–drug conjugates (ADCs), the summit offers a comprehensive programme covering discovery, translational science, clinical development, manufacturing, and regulatory strategy.
ADCs continue to transform oncology, delivering potent therapies directly to cancer cells while minimising off-target toxicity. As the field moves towards earlier-line treatments, developers face complex challenges, from payload optimisation and resistance mechanisms to scalable manufacturing. World ADC London 2026 addresses these challenges head-on, providing actionable insights from 110 global speakers across five content streams over four days of in-depth sessions, workshops, and panel discussions.
This year’s programme highlights next-generation payloads, bispecific constructs, dual-payload strategies, and non-antibody conjugates, giving attendees practical guidance on overcoming resistance, improving safety, and navigating evolving regulatory expectations. Strategic and commercial considerations are also central, with presentations from leading clinicians, regulatory experts, and investors sharing insights into clinical advancement, partnership opportunities, and emerging trends shaping the ADC landscape.
Networking remains a cornerstone of the event, with 14 hours of dedicated interaction built into the agenda. Structured networking sessions, one-to-one meetings, and informal discussions enable delegates to forge collaborations, explore licensing and investment opportunities, and exchange knowledge with peers from across the global ADC community.
Whether you are an early-career scientist, an experienced developer, or a strategic investor, World ADC London 2026 is the must-attend event for staying at the forefront of ADC innovation. From cutting-edge science to strategic insights and invaluable industry connections, the summit empowers participants to advance the next generation of ADCs from the lab to clinical and commercial success.
Contact: info@hansonwade.com | Event Guide | Registration & Pricing